Harris A L
Breast Cancer Res Treat. 1985;6(3):201-11. doi: 10.1007/BF01806770.
Could aminoglutethimide replace adrenalectomy? This question has already been answered in clinical practice in the United Kingdom, for surgical adrenalectomy has declined markedly in frequency as new hormonal therapy has appeared. An optimal assessment of an endocrine therapy can only be made in previously untreated patients because of the heterogeneity of previously treated populations. Thus aminoglutethimide (AG) and adrenalectomy have been compared for previously untreated and treated populations. Because AG is commonly called 'medical adrenalectomy', this article will review and compare aminoglutethimide therapy with surgical adrenalectomy and make the case that surgical adrenalectomy is no longer indicated in the management of breast cancer.
氨鲁米特能否替代肾上腺切除术?在英国的临床实践中,这个问题已经有了答案,随着新的激素疗法出现,手术肾上腺切除术的频率已显著下降。由于既往接受过治疗的人群存在异质性,因此只有在既往未接受过治疗的患者中才能对内分泌疗法进行最佳评估。因此,针对既往未接受过治疗和接受过治疗的人群,对氨鲁米特(AG)和肾上腺切除术进行了比较。由于AG通常被称为“药物性肾上腺切除术”,本文将对氨鲁米特疗法与手术肾上腺切除术进行综述和比较,并论证手术肾上腺切除术在乳腺癌治疗中已不再适用。